NSE filing, NSE: UNITDSPR. Summary written from the filing by ALFA Finder's alert engine.
United Spirits Ltd: key numbers
- Share price
- ₹1,418.00
- Market cap
- ₹1,03,138 Cr
- Revenue (annual)
- ₹12,467 Cr
- Net profit (annual)
- ₹1,838 Cr
- P/E (TTM)
- 55.8×Sector 25.2×
- Promoter holding
- 56.67%+0.00% QoQ
- FII holding
- 12.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from United Spirits Ltd
All →United Spirits Legal & Regulatory
United Spirits disclosed that DRI issued seizure memos under the Customs Act for goods worth about Rs 6.45 Crore. The company says there is no material impact and is seeking provisional release.
- Value
- ₹6.45 Cr
United Spirits ED Probe / Tax Survey
United Spirits' DRI seized goods worth about Rs.6.45 Crore under the Customs Act. The company says there is no material impact on operations.
- Value
- ₹6.45 Cr
United Spirits ED Probe / Tax Survey
United Spirits faced a Maharashtra GST and VAT search, concluded on 29 October 2026. The company reports no impact so far and is fully cooperating.
United Spirits Legal & Regulatory
United Spirits faced a Maharashtra GST and VAT search from October 19 to 29, 2026. Company reports no financial or operational impact and is cooperating fully.
United Spirits Earnings Call Transcript: Key Takeaways
United Spirits delivered resilient 6.3% P&A revenue growth despite significant regulatory headwinds from FSSAI and policy changes. Management remains aggressively optimistic, front-loading marketing spend ahead of the festive season.
- Call
- Guides 10% growth
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.